Haleon (HLN) buys 2.06M shares; voting base updated

Haleon plc announces it purchased 2,062,463 ordinary shares of

Rhea-AI Filing Summary

Haleon plc announces it purchased 2,062,463 ordinary shares of

Positive

• Share buyback executed with 2,062,463 ordinary shares purchased for cancellation under the second tranche of the programme

Negative

• None.

Insights

Financial Analyst

TL;DR Haleon executed a small tranche of its announced buyback, slightly reducing outstanding shares and updating the voting share count.

The Company purchased 2,062,463 ordinary shares for cancellation under the second tranche of its buyback programme announced 31 July 2025. Post-settlement, registered share capital is 8,959,221,411 ordinary shares of and 3,880,205 held as treasury shares, leaving 8,955,341,206 ordinary shares with voting rights. The trade breakdown is available via the provided RNS link. The announcement is procedural and does not constitute an offer for securities.

Corporate Governance Expert

TL;DR Disclosure aligns with Market Abuse Regulation requirements and updates the shareholder voting base following cancellations.

Haleon provided the required Article 5(1)(b) disclosure with a link to individual trades and explicitly stated the updated counts shareholders should use for notification thresholds under the FCA's Disclosure Guidance and Transparency Rules. The filing lists the trading venue as London Stock Exchange CBOE (UK)/CXE and confirms availability of details on the Company's website.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share buyback did Haleon (HLN) announce in this 6-K?

The Company purchased 2,062,463 ordinary shares for cancellation under the second tranche of its buyback programme.

How many voting shares does Haleon have after the transaction?

After settlement there are 8,955,341,206 ordinary shares with voting rights.

How many shares are held as treasury shares?

The filing states 3,880,205 ordinary shares are held as treasury shares.

Where can I find the detailed trade breakdown?

A full breakdown of individual trades is available at the RNS link provided in the filing and on www.haleon.com/investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/02/2025 - 06:11 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	01 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

01 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 2,062,463 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	29 August 2025	29 August 2025	29 August 2025
Number of Shares purchased:	2,062,463	-	-
Highest price paid per Share (p):	364.4000	-	-
Lowest price paid per Share (p):	359.1000	-	-
Volume weighted average price paid per Share (p):	362.5142	-	-

Following the settlement of the above, the Company's registered share capital is 8,959,221,411 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,955,341,206 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/3312X_1-2025-8-29.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 01, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary